4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio
Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.
Zacks·4d ago
More News
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Smart Beta ETF report for PJP
Zacks·1mo ago
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Sector ETF report for PJP
Zacks·2mo ago
Trump To Issue 60-Day Warning Letters To Drugmakers Over Pricing
The U.S. President is expected to send out these letters through his social media platform, Truth Social.
Stocktwits·2mo ago
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Sector ETF report for PPH
Zacks·3mo ago
Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided
Keytruda was first approved in Canada in 2015 and is approved for the treatment of several cancers affecting the bladder, lung, breast, head and neck, and other areas.
Stocktwits·3mo ago
FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report
FDA Commissioner Marty Makary floated the idea in an interview on Bloomberg Television.
Stocktwits·3mo ago
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Smart Beta ETF report for PJP
Zacks·3mo ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Sector ETF report for IHE
Zacks·3mo ago
FDA Aims To Reduce Drug Application Review Time With New Voucher Program
The FDA Commissioner will issue vouchers that drug developers may redeem to participate in a program that will shorten its review time from about 10-12 months to 1-2 months after the company’s final drug application.